Presented at this week's American Society of Nuclear Cardiology annual meeting, the trial found that flurpiridaz F-18-PET met its primary co-endpoints, exceeding a 60% threshold for sensitivity and specificity for detecting coronary artery disease, according to Lantheus and partner GE Healthcare.
The results also showed that flurpiridaz F-18 PET yielded higher diagnostic efficacy and image quality than SPECT MPI, according to the vendors. The phase III open-label study involved over 600 patients across sites in the U.S., Europe, and Canada.
GE has led the funding and development of flurpiridaz F-18 and will hold global commercialization rights if the imaging agent is approved. Meanwhile, Lantheus has collaborated on development and will collaborate on potential commercialization through a joint steering committee, the vendors said.
Copyright © 2022 AuntMinnie.com